Canine Cushing syndrome elevates oxidative stress that is attenuated by trilostane.

IF 1.4 3区农林科学 Q2 VETERINARY SCIENCES

American journal of veterinary research Pub Date : 2025-10-03 DOI:10.2460/ajvr.25.06.0195

Hong Chen, Yuxin Liu, Xian Deng, Yurui Lin, Hanyue Liu, Siyu Zhu, John P Kastelic, Xueying Zhou, Bo Han

{"title":"Canine Cushing syndrome elevates oxidative stress that is attenuated by trilostane.","authors":"Hong Chen, Yuxin Liu, Xian Deng, Yurui Lin, Hanyue Liu, Siyu Zhu, John P Kastelic, Xueying Zhou, Bo Han","doi":"10.2460/ajvr.25.06.0195","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate oxidant-antioxidant status in hyperadrenocorticism (HAC) dogs at diagnosis and after trilostane (Adrestan).Methods: This study, conducted from June 2024 through March 2025, enrolled 25 dogs with HAC and 21 healthy control dogs. Serum malondialdehyde (MDA) concentration, superoxide dismutase (SOD) activity, total oxidant status (TOS), total antioxidant capacity (TAC), and oxidative stress index (OSI) were analyzed before and after treatment.Results: The study included 25 dogs with HAC (14 treated with trilostane, 1 mg/kg, twice daily for 45 days) and 21 healthy controls. At baseline, HAC dogs had significantly elevated oxidative stress markers (MDA, 10.28 μmol/L; TOS, 35.68 μmol H2O2 equivalent (Equiv)/L; OSI, 4.60 arbitrary units (AU)) compared to controls, whereas SOD (44.77 U/mL) and TAC (0.96 mmol/L) remained similar. After trilostane treatment, oxidative stress significantly improved, including decreases in MDA (7.91 → 4.28 μmol/L), TOS (30.82 → 17.85 μmol H2O2 Equiv/L), and OSI (3.61 → 2.14 AU); increased SOD (46.25 → 56.06 U/mL nonsignificant); but no change in TAC (0.97 → 0.94 mmol/L).Conclusions: These findings demonstrated elevated oxidative stress in HAC dogs that was effectively ameliorated by trilostane.Clinical relevance: This study first provides comprehensive documentation of oxidative stress in dogs with HAC and its mitigation after trilostane treatment. Significant oxidative imbalance in canine HAC supports monitoring redox parameters as part of disease management.","PeriodicalId":7754,"journal":{"name":"American journal of veterinary research","volume":" ","pages":"1-7"},"PeriodicalIF":1.4000,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of veterinary research","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.2460/ajvr.25.06.0195","RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate oxidant-antioxidant status in hyperadrenocorticism (HAC) dogs at diagnosis and after trilostane (Adrestan).

Methods: This study, conducted from June 2024 through March 2025, enrolled 25 dogs with HAC and 21 healthy control dogs. Serum malondialdehyde (MDA) concentration, superoxide dismutase (SOD) activity, total oxidant status (TOS), total antioxidant capacity (TAC), and oxidative stress index (OSI) were analyzed before and after treatment.

Results: The study included 25 dogs with HAC (14 treated with trilostane, 1 mg/kg, twice daily for 45 days) and 21 healthy controls. At baseline, HAC dogs had significantly elevated oxidative stress markers (MDA, 10.28 μmol/L; TOS, 35.68 μmol H2O2 equivalent (Equiv)/L; OSI, 4.60 arbitrary units (AU)) compared to controls, whereas SOD (44.77 U/mL) and TAC (0.96 mmol/L) remained similar. After trilostane treatment, oxidative stress significantly improved, including decreases in MDA (7.91 → 4.28 μmol/L), TOS (30.82 → 17.85 μmol H2O2 Equiv/L), and OSI (3.61 → 2.14 AU); increased SOD (46.25 → 56.06 U/mL nonsignificant); but no change in TAC (0.97 → 0.94 mmol/L).

Conclusions: These findings demonstrated elevated oxidative stress in HAC dogs that was effectively ameliorated by trilostane.

Clinical relevance: This study first provides comprehensive documentation of oxidative stress in dogs with HAC and its mitigation after trilostane treatment. Significant oxidative imbalance in canine HAC supports monitoring redox parameters as part of disease management.

查看原文本刊更多论文

犬库欣综合征会升高氧化应激，而三叶烷可以减轻氧化应激。

目的：评价肾上腺皮质亢进症（HAC）犬在诊断时和服用阿德雷斯坦后的氧化-抗氧化状态。方法：本研究于2024年6月至2025年3月进行，招募了25只HAC犬和21只健康对照犬。分析治疗前后血清丙二醛（MDA）浓度、超氧化物歧化酶（SOD）活性、总氧化状态（TOS）、总抗氧化能力（TAC）和氧化应激指数（OSI）。结果：该研究包括25只HAC犬（14只使用trilostane， 1 mg/kg，每天两次，连续45天）和21只健康对照。在基线时，HAC狗的氧化应激标志物显著升高(MDA, 10.28 μmol/L； TOS， 35.68 μmol H2O2当量(Equiv)/L；与对照组相比，OSI为4.60任意单位（AU），而SOD （44.77 U/mL）和TAC （0.96 mmol/L）相似。三叶烷处理后，氧化应激显著改善，MDA（7.91→4.28 μmol/L）、TOS（30.82→17.85 μmol H2O2 Equiv/L）、OSI（3.61→2.14 AU）降低；SOD升高（46.25→56.06 U/mL，差异无统计学意义）；TAC无明显变化（0.97→0.94 mmol/L）。结论：这些发现表明氧化应激升高的HAC犬可以通过三叶曲烷有效地改善。临床相关性：本研究首次提供了HAC犬氧化应激的综合文献，并在trilostane治疗后减轻了氧化应激。犬HAC中显著的氧化失衡支持监测氧化还原参数作为疾病管理的一部分。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American journal of veterinary research 农林科学-兽医学

CiteScore

1.70

自引率

10.00%

发文量

186

审稿时长

3 months

期刊介绍： The American Journal of Veterinary Research supports the collaborative exchange of information between researchers and clinicians by publishing novel research findings that bridge the gulf between basic research and clinical practice or that help to translate laboratory research and preclinical studies to the development of clinical trials and clinical practice. The journal welcomes submission of high-quality original studies and review articles in a wide range of scientific fields, including anatomy, anesthesiology, animal welfare, behavior, epidemiology, genetics, heredity, infectious disease, molecular biology, oncology, pharmacology, pathogenic mechanisms, physiology, surgery, theriogenology, toxicology, and vaccinology. Species of interest include production animals, companion animals, equids, exotic animals, birds, reptiles, and wild and marine animals. Reports of laboratory animal studies and studies involving the use of animals as experimental models of human diseases are considered only when the study results are of demonstrable benefit to the species used in the research or to another species of veterinary interest. Other fields of interest or animals species are not necessarily excluded from consideration, but such reports must focus on novel research findings. Submitted papers must make an original and substantial contribution to the veterinary medicine knowledge base; preliminary studies are not appropriate.